Revenue Recognition in the Age of Biotech Breakthroughs
20+ years of IFRS deal accounting across pharma, biotech, and MedTech — distilled into one practical guide for finance leaders who need to get it right before the deal is signed.
Flip through sample pages or read the full chapter breakdown — your choice.
Ensure accounting treatment is determined before the term sheet is signed, not after.
A working reference for every stage of the deal lifecycle — from structuring to post-close reporting.
Understand the accounting consequences of deal structures before they become constraints Finance must manage for years.
Independent reference for challenging accounting judgements on complex licensing arrangements.
An authoritative reference for IFRS 15 in the life sciences context — bridging the gap between the standard and real-world application.
All formats contain the complete text. Ebook delivers instantly. Print ships via Lulu's local European fulfilment network.
The book provides the principles. The frameworks put them to work on live deals. Buy together and save.
Save €65
Get Starter bundle →Save €131
Get CFO Complete bundle →Save €84
Get Deal Team bundle →Save €278 — the complete MIO Consult toolkit
Get the Full Library →A Must-Read for Anyone Navigating Biotech Finance. Accounting for Innovation is one of the most insightful and timely books I have read on the financial mechanics behind modern life sciences. It takes a notoriously complex topic — biotech revenue recognition — and turns it into a clear, compelling, and surprisingly engaging narrative. What makes this book stand out is its ability to bridge technical accounting rigour with the strategic realities of biotech business models. The case studies are particularly strong. They illuminate how real biotech companies navigate uncertainty, structure deals, and manage investor expectations in an industry where revenue is anything but linear. What I appreciated most is that the book never loses sight of the bigger picture: revenue recognition is not just compliance — it is strategy. Whether you work in biotech finance, audit, corporate development, or simply want to understand how innovation becomes economic value, this book is an essential read. A rare combination of depth, clarity, and relevance.
For publisher, press, rights, or bulk order enquiries, email publishing@michelleolufeso.com directly, or use the form below.
